News | Prostate Cancer | July 02, 2024

The deployment of DL segmentation methods in 18F-fluciclovine PET/CT imaging represents an intriguing research direction for precision medicine in salvage prostate cancer care

The deployment of DL segmentation methods in 18F-fluciclovine PET/CT imaging represents an intriguing research direction for precision medicine in salvage prostate cancer care

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation therapy in prostate cancer.”

In this new editorial, researchers Richard L.J. Qiu, Chih-Wei Chang, and Xiaofeng Yang from Emory University discuss prostate cancer. Prostate cancer persists as the most frequently diagnosed malignancy in men beyond skin cancer. Despite substantial advancements in treatment outcomes over the past half century, progression or recurrence post-initial treatments like prostatectomy or radiation therapy remains a challenge for a subset of patients. 

“In those scenarios, salvage radiation therapy is often offered to patients as a treatment option. To design the salvage radiation therapy, imaging is required to detect and locate the recurrence disease regime.” 

Traditional imaging modalities employed post-prostatectomy, such as CT, bone scans, MRI or 18F-FDG PET, often fall short in accurately detecting and determining the volume of the recurrent disease, which is crucial for salvage radiation treatment planning. However, the introduction of 18F-fluciclovine (anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) PET/CT has marked a significant advancement in salvage disease management. Recent studies, including the phase 2/3 randomized controlled trial, Emory Molecular Prostate Imaging for Radiotherapy Enhancement (EMPIRE-1), demonstrated improved biochemical recurrence or persistence free survival rates when incorporating 18F-fluciclovine PET/CT into post-prostatectomy radiation therapy planning.

One key step in salvage radiation therapy planning is the delineation of lesions on the 18F-fluciclovine PET/CT images, a task currently undertaken manually by physicians. This practice, while meticulous, is labor-intensive and prone to inter- and intra-observer variations. With the recent explosion of using artificial intelligence (AI) algorithms in medical image processing, automatic segmentation of lesions using deep learning (DL)-based lesion delineation methods demonstrate promising potential to improve treatment quality, as opposed to manual contouring. 

For more information: https://www.oncoscience.us/


Related Content

News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News

The Society of Nuclear Medicine and Molecular Imaging's (SNMMI) 2026 Annual Meeting will take place May 30–June 2 in Los ...

Time April 07, 2026
arrow
News | PET Imaging

March 25, 2026 — Catalyst MedTech, a provider of nuclear medicine and molecular imaging solutions, has announced it is ...

Time April 06, 2026
arrow
News | Radiology Business

March 31, 2026 — Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, has has ...

Time March 31, 2026
arrow
News | Radiology Imaging

March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...

Time March 30, 2026
arrow
News | FDA

March 20, 2026 — Siemens Healthineers recently announced its Varian TrueBeam radiotherapy systems, which include ...

Time March 24, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
Subscribe Now